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Allergic reactions to insulin are distinctly unusual with
recombinant human insulin. When they occur, however, they
can be associated with severe symptoms, making it difficult to
treat patients who are insulin-dependent. Whether the increased
use of insulin analogues will further reduce the allergic
manifestations first seen with animal insulin remains uncertain.
Case history
A 57-year-old man with type 2 diabetes presented to the
emergency department of Groote Schuur Hospital, Cape Town,
complaining of an itchy rash which he related to his insulin
injection. He had had diabetes for about 10 years, and had been
switched to insulin (Actraphane twice daily) 1 year previously,
because of poor control with an HbA1c of 9.5% (normal range <
5.8%) on maximal doses of oral agents. There had been
symptomatic improvement after starting the insulin, although
best HbA1c was still poor at 8.8%. Insulin was well tolerated
until 1 month before presentation, when he noted a very itchy
rash on his trunk, neck and arms 1 - 2 hours after injecting. This
persisted for a few hours, improved, and then recurred after his
next injection. The rash had become progressively more severe
over the last month. There was no allergic history otherwise.
About 30 minutes after 10 units of short-acting human
insulin (Humulin R) was administered subcutaneously as a test
dose the patient developed a generalised and severe urticarial
reaction. There was no nasal irritation, peri-orbital oedema or
swelling of the tongue or lips. There was no wheeze or
shortness of breath. His insulin treatment was stopped,
maximal dosages of oral agents were recommenced and strict
dietary habits maintained. However, glycaemic control
deteriorated (HbA1c 12.7%) and symptoms of hyperglycaemia
developed again. He was therefore admitted for insulin
desensitisation.
Skin testing was performed intradermally with dilutions of
human short-acting insulin (Actrapid) and confirmed allergy to
the insulin molecule itself, with a wheal and flare reaction
developing at 0.001 units of insulin. The patient had positive
immunoglobulin E (IgE) antibodies to porcine (1.77 kU/l) and
human insulin (1.29 kU/l).
Desensitisation was carried out over 4 days with
subcutaneous injections of increasing concentrations of human
insulin as per set protocol, after which insulin was much better
tolerated. Occasional allergic reactions still occurred but were
well controlled by antihistamines as needed.
Discussion
Soon after the introduction of animal insulin for the treatment
of diabetes in 1922, immunological complications of insulin
became evident. Insulin allergy was particularly common, with
local symptoms occurring in up to 50% of patients treated with
unchromatographed insulin.1 However, early insulins were
very impure, and were either single species or mixtures of
bovine and porcine insulin, and contained several islet-cell
peptides, which are all immunogenic. With the introduction of
highly purified porcine insulin and recombinant human
insulin, allergic reactions were far less common, occurring in
about 3% and less than 1% of cases respectively.2
By far the most common type of insulin allergy is a type I
hypersensitivity reaction mediated by IgE, which can result in
local or generalised reactions. This biphasic reaction has a
typical time course characterised by an immediate wheal and
flare, followed about 6 hours later by a repeat reaction that
may persist for days. Interestingly, allergy is usually to the
insulin molecule itself. IgE antibodies to insulin are invariably
present and are usually found in high titre in patients with
generalised allergy,3 but may develop in people with no
manifestations of allergy to insulin, and are therefore only
helpful in excluding the diagnosis. Protamine (a complexing
agent to prolong the duration of action of insulin) and zinc
(stabiliser) have also been implicated in insulin allergy. IgE
antibody directed to protamine is common in patients treated
with protamine-containing insulin, but the prevalence of
clinically evident protamine allergy is low.  It is important to
note that a serious generalised reaction to protamine, given to
neutralise heparin anticoagulation following cardiac surgery,
has been described in patients with antibodies to protamine.4
Treatment
Local reactions to insulin tend to be self-limited, with
improvement seen within 1 - 2 months with continued insulin
use. However, if reactions persist for more than 2 weeks, the
following approach is recommended.
1. Rule out poor injection technique, impurities in cleansing
alcohol, and infection.
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2. Switch to human insulin, if the patient is still on animal
insulin. Consider the insulin analogues lispro, aspart or
glargine, which are less immunogenic.5-9
3. If no improvement: (i) reduce the dose given at a single
site by 50%, by using two injection sites; (ii) consider zinc-free
insulin (available from manufacturers); and (iii) use local
steroids in low doses.
4. Consider using long-acting antihistamines.
With such a technique 90% of patients will improve within 2
months,10 and over half of the remainder will improve
spontaneously over 6 - 12 months. If there is deterioration in
the severity of the local reaction it may herald a generalised
reaction and management as for such a reaction is appropriate;
it would be prudent to issue an adrenalin delivery device, e.g.
Epipen (Merck) to manage symptoms of anaphylaxis.
Features of generalised allergy to insulin range in severity
and include urticaria, angio-oedema, pruritus, paraesthesiae,
pallor, flushing, palpitations, bronchospasm, respiratory
distress due to laryngeal oedema and frank circulatory
collapse.  No case of death has been reported.
If evaluated within 24 - 48 hours of a mild, generalised
allergic reaction, consider continuing the insulin, hospitalising
the patient and reducing the dose to 1/3 or 1/4 of the original
and then gradually increasing the dose over several days.11 If
available, it would be prudent to change to insulin analogues.
If insulin therapy has been interrupted for more than 48 hours
or if previous allergic reactions have been particularly severe,
then skin testing and possible desensitisation are indicated.
For such a procedure, the patient is hospitalised and advice
from an experienced diabetologist and allergologist is
recommended. In the presence of significant hyperglycaemia
and/or a deteriorating metabolic condition desensitisation
should be started immediately, otherwise it can be scheduled
electively. In a patient with keto-acidosis, intravenous insulin is
generally well tolerated and can be given until metabolically
stable before attempting desensitisation. Fortunately
desensitisation is effective, with one study reporting a 94%
success rate. 
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